Clinical trial • Phase III • Oncology
KQB198 for Advanced hematologic malignancies | Hematological malignancy
Phase III trial of KQB198 for Advanced hematologic malignancies | Hematological malignancy. 60 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced hematologic malignancies | Hematological malignancy
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 05-09-2024
- First CTIS Authorization Date
- 15-01-2025
Trial design
Phase III trial across 18 sites in France, Germany, Spain and others.
- Target Sample Size
- 60
- Trial Duration For Participant
- 1064
Eligibility
Recruits 60 Vulnerable population not selected; no consent or assent handling information provided..
- Vulnerable Population
- Vulnerable population not selected; no consent or assent handling information provided.
Recruitment
- Planned Sample Size
- 60
- Recruitment Window Months
- 35
- Consent Approach
- No information provided on informed consent or assent; no age-specific consent documents or languages specified.
Geography
- Total Number Of Sites
- 18
- Total Number Of Participants
- 69
France
- Earliest CTIS Part Ii Submission Date
- 16-10-2024
- Latest Decision Or Authorization Date
- 19-01-2026
- Processing Time Days
- 460
- Number Of Sites
- 3
- Number Of Participants
- 12
Sites
- Site Name
- Centre Leon Berard
- Department Name
- Medical oncology
- Principal Investigator Name
- Franck Nicolini
- Principal Investigator Email
- Franck-Emmanuel.NICOLINI@lyon.unicancer.fr
- Contact Person Name
- Franck Nicolini
- Contact Person Email
- Franck-Emmanuel.NICOLINI@lyon.unicancer.fr
- Site Name
- CHU de Tours - Hopital Bretonneau
- Department Name
- Hematology
- Principal Investigator Name
- Antoine MACHET
- Principal Investigator Email
- a.machet@chu-tours.fr
- Contact Person Name
- Antoine MACHET
- Contact Person Email
- a.machet@chu-tours.fr
- Site Name
- Hôpital de la Timone
- Department Name
- Centre d'Essais Précoces en Cancérologie de Marseille (CEPCM)
- Principal Investigator Name
- Regis Costello
- Principal Investigator Email
- Regis.COSTELLO@ap-hm.fr
- Contact Person Name
- Regis Costello
- Contact Person Email
- Regis.COSTELLO@ap-hm.fr
Germany
- Earliest CTIS Part Ii Submission Date
- 21-11-2024
- Latest Decision Or Authorization Date
- 21-01-2026
- Processing Time Days
- 426
- Number Of Sites
- 2
- Number Of Participants
- 12
Sites
- Site Name
- Universitaetsklinikum Jena KöR
- Department Name
- Hematology and internal Oncology
- Principal Investigator Name
- Andreas Hochhaus
- Principal Investigator Email
- Andreas.Hochhaus@med.uni-jena.de
- Contact Person Name
- Andreas Hochhaus
- Contact Person Email
- Andreas.Hochhaus@med.uni-jena.de
- Site Name
- Medizinische Hochschule Hannover
- Department Name
- Hematology, Hemostasis, Oncology and Stem Cell Transplantation
- Principal Investigator Name
- Susanne Isfort
- Principal Investigator Email
- isfort.susanne@mh-hannover.de
- Contact Person Name
- Susanne Isfort
- Contact Person Email
- isfort.susanne@mh-hannover.de
Spain
- Earliest CTIS Part Ii Submission Date
- 08-11-2024
- Latest Decision Or Authorization Date
- 23-01-2026
- Processing Time Days
- 441
- Number Of Sites
- 4
- Number Of Participants
- 9
Sites
- Site Name
- Hospital Universitario Regional De Malaga
- Department Name
- Hematology and Hemotherapy
- Principal Investigator Name
- Maria Concepcion Ruiz Nuno
- Principal Investigator Email
- conchirn@hotmail.com
- Contact Person Name
- Maria Concepcion Ruiz Nuno
- Contact Person Email
- conchirn@hotmail.com
- Site Name
- Hospital Universitario La Paz
- Department Name
- Hematology and Hemotherapy
- Principal Investigator Name
- Raquel De Paz Arias
- Principal Investigator Email
- depazraquel@gmail.com
- Contact Person Name
- Raquel De Paz Arias
- Contact Person Email
- depazraquel@gmail.com
- Site Name
- Institut Catala D'oncologia
- Department Name
- Hematology
- Principal Investigator Name
- Jasson Villarreal Hernández
- Principal Investigator Email
- jvillarreal@iconcologia.net
- Contact Person Name
- Jasson Villarreal Hernández
- Contact Person Email
- jvillarreal@iconcologia.net
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Hematology
- Principal Investigator Name
- Joaquin Martinez Lopez
- Principal Investigator Email
- jmarti01@med.ucm.es
- Contact Person Name
- Joaquin Martinez Lopez
- Contact Person Email
- jmarti01@med.ucm.es
Poland
- Earliest CTIS Part Ii Submission Date
- 02-12-2024
- Latest Decision Or Authorization Date
- 26-01-2026
- Processing Time Days
- 420
- Number Of Sites
- 4
- Number Of Participants
- 12
Sites
- Site Name
- Aidport Sp. z o.o.
- Department Name
- AIDPORT SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Principal Investigator Name
- Michał Kwiatek
- Principal Investigator Email
- michal.kwiatek@aidport.pl
- Contact Person Name
- Michał Kwiatek
- Contact Person Email
- michal.kwiatek@aidport.pl
- Site Name
- Pratia Hematologia Sp. z o.o.
- Department Name
- Pratia Onkologia Katowice
- Principal Investigator Name
- Sebastian Grosicki
- Principal Investigator Email
- sgrosicki@wp.pl
- Contact Person Name
- Sebastian Grosicki
- Contact Person Email
- sgrosicki@wp.pl
- Site Name
- Copernicus Podmiot Leczniczy Sp. z o.o.
- Department Name
- Wojewódzkie Centrum Onkologii
- Principal Investigator Name
- Hanna Ciepłuch
- Principal Investigator Email
- ciepluch@gumed.edu.pl
- Contact Person Name
- Hanna Ciepłuch
- Contact Person Email
- ciepluch@gumed.edu.pl
- Site Name
- Uniwersyteckie Centrum Kliniczne
- Department Name
- Klinika Hematologii i Transplantologii
- Principal Investigator Name
- Witold Prejzner
- Principal Investigator Email
- wpre@gumed.edu.pl
- Contact Person Name
- Witold Prejzner
- Contact Person Email
- wpre@gumed.edu.pl
Italy
- Earliest CTIS Part Ii Submission Date
- 27-11-2024
- Latest Decision Or Authorization Date
- 25-02-2026
- Processing Time Days
- 455
- Number Of Sites
- 4
- Number Of Participants
- 15
Sites
- Site Name
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
- Department Name
- Ematologia
- Principal Investigator Name
- Fausto Castagnetti
- Principal Investigator Email
- fausto.castagnetti@unibo.it
- Contact Person Name
- Fausto Castagnetti
- Contact Person Email
- fausto.castagnetti@unibo.it
- Site Name
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Department Name
- DIAGNOSTICA PER IMMAGINI, RADIOTERAPIA ONCOLOGICA ED EMATOLOGIA
- Principal Investigator Name
- Federica Sorà
- Principal Investigator Email
- FEDERICA.SORA@UNICATT.IT
- Contact Person Name
- Federica Sorà
- Contact Person Email
- FEDERICA.SORA@UNICATT.IT
- Site Name
- ASST Grande Ospedale Metropolitano Niguarda
- Department Name
- Ematologia
- Principal Investigator Name
- Marianna Caramella
- Principal Investigator Email
- marianna.caramella@ospedaleniguarda.it
- Contact Person Name
- Marianna Caramella
- Contact Person Email
- marianna.caramella@ospedaleniguarda.it
- Site Name
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
- Department Name
- Ematologia
- Principal Investigator Name
- Alessandra Iurlo
- Principal Investigator Email
- alessandra.iurlo@policlinico.mi.it
- Contact Person Name
- Alessandra Iurlo
- Contact Person Email
- alessandra.iurlo@policlinico.mi.it
Netherlands
- Earliest CTIS Part Ii Submission Date
- 27-03-2025
- Latest Decision Or Authorization Date
- 20-01-2026
- Processing Time Days
- 299
- Number Of Sites
- 1
- Number Of Participants
- 9
Sites
- Site Name
- Radboud universitair medisch centrum Stichting
- Department Name
- Department of Hematology
- Principal Investigator Name
- Jeroen Janssen
- Principal Investigator Email
- jeroen.janssen1@radboudumc.nl
- Contact Person Name
- Jeroen Janssen
- Contact Person Email
- jeroen.janssen1@radboudumc.nl
Sponsor
Primary sponsor
- Full Name
- Kumquat Biosciences Inc.
- Organisation Type
- Laboratory/Research/Testing facility
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- KQB198
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)